Navigation Links
Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
Date:10/6/2010

considered meaningful to women.  This latter point was further demonstrated by significant improvements in limitations in social or leisure and physical activities, and work inside or outside the home in women receiving LYSTEDA compared with those receiving placebo," stated Andrea Lukes, MD, MHSc, lead study investigator, Carolina Women's Research and Wellness Center.  "LYSTEDA offers clinicians a first-line, non-hormonal treatment option for women with cyclic heavy menstrual bleeding."

"We are pleased to present these data that add to the existing body of evidence demonstrating the safety and efficacy of LYSTEDA in the treatment of cyclic heavy menstrual bleeding," said Edward A. Trott, MD, Vice President of Medical Affairs, Ferring Pharmaceuticals Inc. "Women in the study experienced a significant reduction in menstrual blood loss, as early as the first cycle of use, which was maintained throughout all treatment cycles.  In addition to the reduction in monthly blood loss, there was a statistically significant improvement in the health-related quality-of-life parameters for social, leisure and physical activities."

LYSTEDA's Unique Mechanism of Action

LYSTEDA works to slow the breakdown of clots thereby reducing cyclic HMB.  LYSTEDA does not cause clots and has no effect on clotting factors or platelet function.*

In the fibrinolytic pathway, tissue plasminogen activator binds with plasminogen, cleaving it to the active form of the enzyme plasmin.  This activated enzyme binds the fibrin mesh that holds a clot together and cleaves it, allowing the clot to break apart.  Many HMB patients have higher levels of plasminogen activators than those with normal bleeding.  For those patients, fibrinolysis breaks down the normal fibrin matrix in the endometrium, causing a more rapid breakdown of the blood clot and excessive blood loss.  LYSTEDA binds to the fibrin-binding site of plasmin, preventing it
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
2. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
3. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
8. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
9. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
10. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... Dec. 24, 2014  Conkwest, Inc., the Natural ... proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) ... Patrick Soon-Shiong , NantWorks founder, physician scientist and ... to purchase approximately $48 million of the Company,s ... investment, he will be named Co-Chairman of the ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Show Superior Decrease in Pain Scores Compared to Saline ... the results of a six-month safety and efficacy study ... decreasing the pain of knee osteoarthritis (OA) at 26 ... superior to saline in decreasing pain at 26 weeks ...
... Phase 3 Avanafil Study REVIVE (TA-301) is Complete MOUNTAIN ... VVUS ), a biopharmaceutical company developing innovative, next-generation ... sexual health, today announced that it has initiated an ... avanafil, in males with erectile dysfunction (ED). VIVUS ...
Cached Medicine Technology:Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 2Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 3VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Tube-Feeding Best-Practice Recommendations NEW ORLEANS, Feb. 3 ... HealthCare Nutrition and the American Society for Parenteral ... launch of a new initiative to promote safe ... designed to raise awareness of key steps that ...
... LEXINGTON, Ky., Feb. 3 Just because the economy isn,t ... a Valentine,s surprise for that,special someone. Now,s the time ... from discounted treatments to complimentary services. Roses wilt,and chocolates melt, ... not only a,romantic gift but a healthful one too. , ...
... out the bumps in aesthetic skin care with its latest offering. ... the UniForm handpiece, recently approved by the FDA for cellulite treatment. ... ... seeking painless cellulite treatment, New York City based Juva Skin and ...
... (February 2, 2009) New research published in the ... College of Surgeons suggests that a traditional, "open" ... for the majority of patients with acute appendicitis, contrary ... are performed in the United States each year to ...
... Feb. 2 Smith & Nephew,s Advanced Wound ... announced that the U.S. Court of Appeals for the Federal ... 1 negative pressure wound therapy system marketed by Blue Sky ... Sky in May 2007."Smith & Nephew welcomes the appeals court ...
... Living: The Financial Options Guide Now Available at Sunrise ... Senior Living (NYSE: SRZ ) now offers ... families identify ideas for affording senior care in today,s ... Living: The Financial Options , is available at Sunrise ...
Cached Medicine News:Health News:Nestle HealthCare Nutrition and Medical Professionals Unite to Improve Patient Safety 2Health News:Nestle HealthCare Nutrition and Medical Professionals Unite to Improve Patient Safety 3Health News:Nestle HealthCare Nutrition and Medical Professionals Unite to Improve Patient Safety 4Health News:Rev Up the Romance this Valentine's Day with Savvy Spa Savings 2Health News:Juva Skin Banishes Bumps with New UniForm Cellulite Therapy Handpiece 2Health News:Treating appendicitis by laparoscopic surgery may not be worth the cost 2Health News:U.S. Court of Appeals Rules That Smith & Nephew Does Not Infringe KCI Patents 2Health News:U.S. Court of Appeals Rules That Smith & Nephew Does Not Infringe KCI Patents 3Health News:Sunrise Senior Living Helps Families Explore Senior Care Financing Options with New Guide 2
Designed to give maximum drying area while taking up minimal bench space....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Thermostatically controlled, large capacity surface to quickly evaporate water and solvents from slides and mounting media....
Compact instrument that quickly dries racks of slides using warm air....
Medicine Products: